Shreya Sridhar

[ACCP Cardiology PRN @accpcardprn]

A new patient-facing infographic about Lp(a) from #CardioSmart @ACCinTouch

[American College of Cardiology @ACCinTouch]

“Guidelines baby… we got 🆕 guidelines baby.” 🎤

A creative take on the 2026 Dyslipidemia Guideline that breaks down key takeaways with a beat. 👇

📖 Read the full guideline in JACC: https://t.co/OqJngLhZ4I #ClinicalGuidelines #cvLipids @JACCJournals

[European Atherosclerosis Society @society_eas]

The @nationallipid has published an important new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse cardiovascular events (MACE) in primary prevention populations.

The study synthesizes data from randomized trials of both statin and non-statin therapies and updates the landmark 2012 analysis from the Cholesterol Treatment Trialists’ Collaboration.

Prof. @ProfKausikRay said: "I was honoured to collaborate with NLA colleagues on this important research. This systematic review and meta-analysis of all available trial data in patients without pre-existing cardiovascular disease demonstrates that, irrespective of how LDL cholesterol is lowered, there are greater relative benefits than expected compared with starting treatment in patients with pre-existing disease.

The findings are immediately actionable and should be used by clinicians in shared decision-making. This greater ‘return on investment’ per 1 mmol/L reduction suggests that health systems should prioritise primary prevention earlier as a means to reduce the global burden of cardiovascular disease."

The full article is available here: https://t.co/9T4mZkjoyO